Genmab, Immatics Launch Up-to-$2.8B+ Cancer Immunotherapy Partnership

Genmab will partner with Immatics Biotechnologies to discover and develop next-generation bispecific cancer immunotherapies through a collaboration that could generate more than $2.8 billion for Immatics, the companies said today.The companies have launched a research collaboration designed to combine Genmab's technologies and antibody expertise with Immatics' XPRESIDENT ®targets and T-cell receptor (TCR) capabilities.Immatics agreed to grant Genmab an exclusive license to three of its propr